Atara Biotherapeutics To Participate at the Stifel Healthcare Conference

Rhea-AI Summary

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) to present at Stifel Healthcare Conference on November 14, 2023, discussing T-cell immunotherapy and EBV T-cell platform. Pascal Touchon, President and CEO, to participate in a fireside chat at 8:30 a.m. PST / 11:30 a.m. EST. Webcast available on atarabio.com.

Positive

• Atara Biotherapeutics participating in Stifel Healthcare Conference demonstrates the company's commitment to engaging with the investment community and showcasing their innovative therapies.
• The focus on T-cell immunotherapy and leveraging the EBV T-cell platform aligns with the current trend towards personalized and targeted treatments for cancer and autoimmune diseases.

Negative

• None.

THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the Stifel Healthcare Conference in New York on Tuesday, November 14, 2023 at 8:30 a.m. PST / 11:30 a.m. EST.

A live webcast of the presentation will be available by visiting the Investors and Media section of atarabio.com. An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.

About Atara Biotherapeutics, Inc.

Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions, including multiple sclerosis, that can be rapidly delivered to patients within days. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile Epstein-Barr virus (EBV) T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of non-EBV-associated liquid and solid tumors. Atara is headquartered in Southern California. For more information, visit atarabio.com and follow @Atarabio on X (formerly known as Twitter) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231109837801/en/

Investor and Media Relations

Alex Chapman

Vice President, Corporate Communications & Investor Relations

(805) 456-4772

achapman@atarabio.com



Jason Awe, Ph.D.

Senior Director, Corporate Communications & Investor Relations

(805) 217-2287

jawe@atarabio.com

Source: Atara Biotherapeutics, Inc.

FAQ

What is Atara Biotherapeutics presenting at the Stifel Healthcare Conference?

Atara Biotherapeutics will be discussing their T-cell immunotherapy and EBV T-cell platform, highlighting transformative therapies for cancer and autoimmune diseases.

When will Pascal Touchon participate in the fireside chat?

Pascal Touchon will be participating in the fireside chat on Tuesday, November 14, 2023, at 8:30 a.m. PST / 11:30 a.m. EST.

Where can I access the webcast of the presentation?

The webcast will be available on the Investors and Media section of atarabio.com, with an archived replay available for 30 days following the live presentation.